Abstract:BACKGROUND & AIMS: RNA N-6-methyladenosine (m(6)A) modification has recently emerged as a new regulatory mechanism in cancer progression. We aimed to explore the role of the m(6)A regulatory enzyme METTL3 in colorectal cancer (CRC) pathogenesis and its potential as a therapeutic target. METHODS: The expression and clinical implication of METTL3 were investigated in multiple human CRC cohorts. The underlying mechanisms of METTL3 in CRC were investigated by integrative m(6)A sequencing, RNA sequencing, and ribosome profiling analyses. The efficacy of targeting METTL3 in CRC treatment was elucidated in CRC cell lines, patient-derived CRC organoids, and Mettl3-knockout mouse models. RESULTS: Using targeted clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 dropout screening, we identified METTL3 as the top essential m(6)A regulatory enzyme in CRC. METTL3 was overexpressed in 62.2% (79/127) and 88.0% (44/50) of primary CRCs from 2 independent cohorts. High METTL3 expression predicted poor survival in patients with CRC (n = 374, P < .01). Functionally, silencing METTL3 suppressed tumorigenesis in CRC cells, human-derived primary CRC organoids, and Mettl3-knockout mouse models. We discovered the novel functional m(6) A methyltransferase domain of METTL3 in CRC cells by domain-focused CRISPR screening and mutagenesis assays. Mechanistically, METTL3 directly induced the m(6)A-GLUT1-mTORC1 axis as identified by integrated m6A sequencing, RNA sequencing, ribosome sequencing, and functional validation. METTL3 induced GLUT1 translation in an m(6)A-dependent manner, which subsequently promoted glucose uptake and lactate production, leading to the activation of mTORC1 signaling and CRC development. Furthermore, inhibition of mTORC1 potentiated the anticancer effect of METTL3 silencing in CRC patient-derived organoids and METTL3 transgenic mouse models. CONCLUSIONS: METTL3 promotes CRC by activating the m(6)A-GLUT1-mTORC1 axis. METTL3 is a promising therapeutic target for the treatment of CRC.

Proteome-wide Interrogation of Small GTPases Regulated by N6-Methyladenosine Modulators

Retraction Note: RNA M6a Methylation Regulates the Epithelial Mesenchymal Transition of Cancer Cells and Translation of Snail.

Targeted Manipulation of Cellular RNA m6A Methylation at theSingle-Base Level br

Effects of RNA Methylation N6-methyladenosine Regulators on Malignant Progression and Prognosis of Melanoma.

An RNA Methylation-Sensitive AIEgen-Aptamer Reporting System for Quantitatively Evaluating M6a Methylase and Demethylase Activities

METTL5, an 18S Rrna-Specific M6a Methyltransferase, Modulates Expression of Stress Response Genes

New insights into the dynamics of m6A epitranscriptome: hybrid-seq identifies novel mRNAs of the m6A writers METTL3/14

METTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis

SUMOylation of the M6a-Rna Methyltransferase METTL3 Modulates Its Function.

Modulation of N-terminal methyltransferase 1 by an N6-methyladenosine-based epitranscriptomic mechanism.

N6-Methyladenosine Regulates the Expression and Secretion of TGFβ1 to Affect the Epithelial–Mesenchymal Transition of Cancer Cells

The Development of Small Molecules Targeting Methyltransferase-Like 3

m6A regulates breast cancer proliferation and migration through stage-dependent changes in Epithelial to Mesenchymal Transition gene expression

m3C32 tRNA modification controls serine codon-biased mRNA translation, cell cycle, and DNA-damage response

Stabilization of ERK-Phosphorylated METTL3 by USP5 Increases m6A Methylation

A Targeted Quantitative Proteomic Approach Assesses the Reprogramming of Small GTPases During Melanoma Metastasis

The Emerging Roles of RNA m6A Methylation and Demethylation as Critical Regulators of Tumorigenesis, Drug Sensitivity, and Resistance

RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the M6a-Glut1-mtorc1 Axis and is a Therapeutic Target

N6-Methyladenosine Modulates Nonsense-Mediated mRNA Decay in Human Glioblastoma

Unraveling the independent role of METTL3 in m6A modification and tumor progression in esophageal squamous cell carcinoma

The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer